Noble Capital Markets Initiates Coverage On Cadrenal Therapeutics with Outperform Rating, Announces Price Target of $4
Portfolio Pulse from Benzinga Newsdesk
Noble Capital Markets analyst Robert LeBoyer has initiated coverage on Cadrenal Therapeutics with an Outperform rating and set a price target of $4. The company is listed on NASDAQ under the ticker CVKD.
December 18, 2023 | 2:09 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cadrenal Therapeutics received an Outperform rating from Noble Capital Markets with a price target of $4, indicating a positive outlook from the analyst.
Analyst ratings, especially initiations of coverage with positive outlooks, can lead to increased investor interest and potential stock price appreciation. The Outperform rating and $4 price target suggest that Noble Capital Markets expects CVKD to perform well in the market, which could influence investor sentiment positively in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100